Date Headline Docs
14 Sep 2017 Targovax Receives 2017 Nordic Stars Award
12 Sep 2017 Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
11 Sep 2017 Targovax ASA: Three posters presented at ESMO conference
29 Aug 2017 Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units
28 Aug 2017 Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
25 Aug 2017 Exercise of employee share options and restricted stock units in Targovax ASA
24 Aug 2017 Targovax ASA: Second quarter and first half 2017 results
23 Aug 2017 Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress
18 Aug 2017 Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
14 Aug 2017 Targovax ASA: Invitation to second quarter and first half 2017 results presentation Thursday 24 August
17 Jul 2017 Targovax ASA: Final result of the subsequent offering
14 Jul 2017 Targovax ASA: Preliminary result of the subsequent offering
14 Jul 2017 Targovax ASA: Last day of the subscription period in the subsequent offering
07 Jul 2017 Targovax ASA: Notification of trade by primary insiders
06 Jul 2017 Targovax ASA: Registration of share capital increase following the private placement
03 Jul 2017 Targovax ASA: Commencement of subscription period for the subsequent offering
30 Jun 2017 Targovax ASA: Approval and publication of prospectus; the subsequent offering
30 Jun 2017 Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
26 Jun 2017 Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units
22 Jun 2017 Targovax ASA: Mandatory notification of trade by primary insider in relation to exercise of employee options
22 Jun 2017 Targovax ASA: Exercise of employee share options and settlement of restricted stock units in Targovax ASA
15 Jun 2017 Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of vested restricted stock units
14 Jun 2017 Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
09 Jun 2017 Targovax ASA: Notice of Extraordinary General Meeting
09 Jun 2017 Targovax ASA - Information on the subsequent offering - Key date information
08 Jun 2017 TARGOVAX ASA - SUCCESSFULLY COMPLETED PRIVATE PLACEMENT
08 Jun 2017 TARGOVAX ASA - CONTEMPLATED PRIVATE PLACEMENT
06 Jun 2017 Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
06 Jun 2017 Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London
18 May 2017 Targovax ASA: ASCO abstract released
10 May 2017 Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
08 May 2017 Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017
28 Apr 2017 Targovax ASA: Issuance of restricted stock unites (RSUs) to the board members
25 Apr 2017 Targovax ASA: First quarter 2017 results
20 Apr 2017 Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
19 Apr 2017 Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
06 Apr 2017 Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
05 Apr 2017 Targovax ASA: Protocol from the Annual General Meeting
04 Apr 2017 Targovax ASA: Proposal from the nomination committee to the annual general meeting 5 April 2017
23 Mar 2017 Targovax ASA moves share listing to Oslo BÝrs
22 Mar 2017 Targovax ASA: Approval and publication listing prospectus
22 Mar 2017 Targovax ASA: The board of directors of Oslo Stock Exchange approves transfer of Targovax ASA to the main list
17 Mar 2017 Targovax ASA applies for transfer to Oslo Stock Exchange main list
15 Mar 2017 Targovax ASA: Notice of Annual General Meeting
15 Mar 2017 Targovax ASA: Annual Report 2016
06 Mar 2017 Targovax to present at upcoming conferences
24 Feb 2017 Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units
24 Feb 2017 Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
16 Feb 2017 Targovax ASA: Fourth quarter and full year 2016 results
13 Feb 2017 Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of restricted stock units
10 Feb 2017 Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
06 Feb 2017 Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February
02 Feb 2017 Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
05 Jan 2017 Targovax announces appointment of Erik Digman Wiklund as CFO
Date Headline Docs
13 Dec 2016 Targovax to present at DNB healthcare conference
09 Dec 2016 Targovax ASA: Grant of share options
21 Nov 2016 Targovax ASA: Registration of share capital increase following exercise of employee options
21 Nov 2016 Targovax ASA: Exercise of employee share options in Targovax ASA
18 Nov 2016 Targovax ASA: Mandatory notification of trade by primary insider
17 Nov 2016 Targovax ASA: Third quarter 2016 results
16 Nov 2016 Targovax to present at forthcoming conference
10 Nov 2016 Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
08 Nov 2016 Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November
04 Nov 2016 Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
02 Nov 2016 Targovax ASA: GRANT OF SHARE OPTIONS
02 Nov 2016 Targovax announces appointment of Oystein Soug as CEO
21 Oct 2016 Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
17 Oct 2016 Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium
19 Sep 2016 Targovax to present at Redeye's Fight Cancer conference
14 Sep 2016 Targovax to present at forthcoming conferences
25 Aug 2016 Targovax ASA: Interim Report second quarter and first half year 2016
17 Aug 2016 Targovax ASA: Completion of subsequent offering, registration of share capital increase
15 Aug 2016 Targovax ASA: Invitation to second quarter 2016 results presentation Thursday 25 August
09 Aug 2016 Targovax ASA: Allocations to primary insiders in the subsequent offering
09 Aug 2016 Targovax ASA: Result of the subsequent offering
08 Aug 2016 Targovax ASA - Last day of the subscription period in the subsequent offering
04 Aug 2016 Targovax ASA - The subscription period in the subsequent offering expires on Monday 8 August at 16:30 CET
11 Jul 2016 Targovax ASA: Commencement of subscription period for the subsequent offering
08 Jul 2016 Targovax ASA: Publication of prospectus, listing on Oslo Axess and subsequent offering
07 Jul 2016 Targovax ASA: Completion of private placement, registration of share capital increase
06 Jul 2016 Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
06 Jul 2016 Targovax presents encouraging preclinical data on ONCOS-102
01 Jul 2016 Targovax ASA: Applies for listing of its shares on Oslo Axess
01 Jul 2016 Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
22 Jun 2016 Targovax ASA: Announcement of successful NOK 110 million private placement
21 Jun 2016 Targovax ASA: Update on bookbuilding for the private placement of NOK 100 - 130 million
20 Jun 2016 Targovax ASA: Contemplated private placement of NOK 100 - 130 million
15 Jun 2016 Targovax ASA: Price per share sold by member of the management
14 Jun 2016 Targovax granted US Patent for oncolytic virus ONCOS-102
09 Jun 2016 Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102
07 Jun 2016 Targovax ASA: Patient recruitment for TG01 immuno-oncology trial completed
02 Jun 2016 Targovax receives approval in Australia to conduct a clinical trial withTG02 - an immunotheraphy treatment targeting RAS mutations
31 May 2016 Targovax to present at forthcoming conferences
12 May 2016 Targovax ASA: Interim report first quarter 2016
09 May 2016 Targovax ASA: Registration of share capital increase following exercise of employee options
09 May 2016 Targovax to present at BioEquity Europe and its first quarter 2016 results on May 11 - 12, 2016
29 Apr 2016 Exercise of employee share options in Targovax ASA
15 Apr 2016 Targovax ASA: Grant of restricted stock units to the Board of directors
14 Apr 2016 Targovax reports immune response with reduced number of TG01 vaccinations
14 Apr 2016 Resolution to increase the share capital in Targovax ASA in relation to exercise of employee options
13 Apr 2016 Targovax ASA: Protocol from the Annual General Meeting
14 Mar 2016 Targovax to present at forthcoming Life Science and Investor conferences
10 Mar 2016 Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
02 Mar 2016 Targovax ASA: Interim report fourth quarter 2015
25 Feb 2016 CORRECTION: Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
25 Feb 2016 Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation
02 Feb 2016 Targovax submits a study of its adenovirus based immune therapy ONCOS-102 to the regulatory authorities in Spain
Date Headline Docs
26 Nov 2015 Targovax ASA: Interim report third quarter 2015
19 Nov 2015 Targovax ASA: Invitation to presentation of Targovax' third quarter 2015 results
18 Nov 2015 Targovax ASA: LUDWIG CANCER RESEARCH AND CANCER RESEARCH INSTITUTE PARTNER WITH TARGOVAX TO TEST CANDIDATE VIROTHERAPY IN EARLY-PHASE CLINICAL TRIALS
06 Nov 2015 Targovax to present at upcoming investor Conferences
Date Headline Docs
No Stock Exchange Notices available for this period